Cowen Reiterates Buy Rating for Aptinyx (NASDAQ:APTX)

Cowen reissued their buy rating on shares of Aptinyx (NASDAQ:APTX) in a research report report published on Wednesday, AnalystRatings.com reports.

Several other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aptinyx in a research report on Wednesday, October 14th. They set a neutral rating for the company. BMO Capital Markets restated a buy rating and set a $13.00 price objective on shares of Aptinyx in a research report on Friday, August 14th. SunTrust Banks assumed coverage on shares of Aptinyx in a research report on Wednesday, July 1st. They set a buy rating and a $15.00 price objective for the company. SVB Leerink raised their price objective on shares of Aptinyx from $12.00 to $14.00 and gave the company an outperform rating in a research report on Tuesday, October 20th. Finally, William Blair restated a buy rating on shares of Aptinyx in a research report on Thursday, October 1st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Aptinyx currently has an average rating of Buy and a consensus price target of $10.25.

Shares of APTX opened at $3.13 on Wednesday. The firm has a 50-day moving average price of $3.45 and a 200 day moving average price of $3.65. The firm has a market capitalization of $146.75 million, a PE ratio of -2.14 and a beta of 1.21. Aptinyx has a 52-week low of $1.60 and a 52-week high of $6.47.

Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. Aptinyx had a negative net margin of 1,764.55% and a negative return on equity of 49.15%. The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.84 million. As a group, research analysts anticipate that Aptinyx will post -1.23 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP lifted its position in shares of Aptinyx by 5.0% in the second quarter. Two Sigma Advisers LP now owns 105,800 shares of the company’s stock worth $441,000 after purchasing an additional 5,000 shares in the last quarter. UBS Group AG lifted its position in shares of Aptinyx by 2,549.0% in the second quarter. UBS Group AG now owns 7,947 shares of the company’s stock worth $33,000 after purchasing an additional 7,647 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Aptinyx in the second quarter worth approximately $37,000. Leap Investments LP purchased a new stake in shares of Aptinyx in the second quarter worth approximately $58,000. Finally, American International Group Inc. purchased a new stake in shares of Aptinyx in the second quarter worth approximately $63,000. 59.26% of the stock is owned by institutional investors.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: Death Cross

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.